LN-229 In Vivo Tumorigenesis Assay

This assay is to provide LN-229-based In Vivo Tumorigenesis Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

LN-229

Human

The LN-229 cell line was established in 1979 from cells taken from a patient with right frontal parieto-occipital glioblastoma [PubMed. 10416987].

Glioblastoma

Oncology

In Vivo Tumorigenesis Assay

LN-229-cell based In Vivo Tumorigenesis Assay

Tumorigenicity is defined the property of a cell to form tumors when inoculated into an immunosuppressed animal model. Generally, test cells and tumor cells as positive control are administered subcutaneously into immunosuppressed nude mice. The number of animals developing tumors are compared with a positive control reference cell line.

Oncology In Vivo Assays